The Daily

Reuters’ framing is blunt: China’s current “agent craze” is now an enterprise product race. Alibaba’s new platform, Wukong, is positioned as a single interface that can coordinate multiple AI agents for everyday business workflows. Examples given include document editing, spreadsheet updates, meeting transcription, and research — the boring-but-expensive layer where time actually disappears inside companies. It’s currently invitation-only beta, which suggests Alibaba is optimizing reliability and guardrails before a broad launch. Distribution is the real play: Wukong is available as a desktop app and also through DingTalk, Alibaba’s collaboration platform with 20+ million corporate users. Next step to watch: integrations beyond Alibaba’s stack (Reuters says connections to Slack, Microsoft Teams, and WeChat) — because agents only matter when they can act where the work is.

This is less about a new feature drop and more about Microsoft admitting that adoption is the battle. Reuters reports that Microsoft is reorganizing Copilot by unifying its consumer and commercial product teams into one effort. The immediate consequence is political: it frees up AI chief Mustafa Suleyman to focus on building new models and the company’s “superintelligence” program over the next five years. Microsoft also disclosed concrete usage signals: consumer Copilot daily app users have nearly tripled year-over-year, while M365 Copilot (priced at $30/month) has reached 15 million annual users. The competitive context matters, too: Reuters explicitly calls out stronger reception for Google’s Gemini and autonomous agents like Anthropic’s Claude Cowork as pressure on Microsoft’s AI narrative. What to watch next is whether the org change turns into cleaner product surface area — fewer Copilots, fewer conflicting experiences, and faster iteration.

The headline number is almost absurd on purpose: Reuters reports Amazon’s CEO says AI could push AWS to $600 billion in revenue by 2036. The point isn’t that anyone can forecast a decade out with accuracy — it’s that hyperscalers are using AI demand to justify massive, continuous infrastructure spend. If you believe those curves, then data centers, power contracts, and accelerator supply chains become the real competitive moat, not just model quality. It also reframes enterprise AI as a multi-year migration of workloads (and budgets) rather than a set of “pilot projects.” The near-term signal to watch is whether AWS can translate that capex into durable pricing power, or whether competition forces the gains back to customers as cheaper compute. Either way, it’s a reminder: the AI boom is being financed like a new utilities build-out.

This is what “data package risk” looks like in public. Fierce Biotech reports the FDA issued a complete response letter to Aldeyra’s reproxalap (a RASP modulator) — the third rejection for the dry-eye program. The agency’s core critique is unusually direct: a lack of “substantial evidence” from adequate, well-controlled investigations and an inability to demonstrate efficacy. Aldeyra had pointed to a Phase 3 chamber trial where reproxalap significantly improved eye discomfort versus placebo, but the FDA says inconsistency across studies raises serious concerns about the reliability and meaningfulness of the positive findings. Importantly, the FDA did not explicitly request a new trial in the CRL; instead, it suggested the company investigate why certain trials failed and identify populations/conditions where the drug might work. The “next step” is procedural: Aldeyra plans to request a Type A meeting (supposed to be held within 30 days of request) to clarify what would be required for approval.

R1’s pitch is “old problem, new mechanism.” Fierce Biotech says the company raised an oversubscribed $77.5M Series A, co-led by Abingworth, F-Prime Capital and DaVita Venture Group. The asset is AP306, licensed globally from China-based Alebund, described as a pan-phosphate transporter inhibitor intended as a monotherapy for hyperphosphatemia in CKD patients on dialysis. The market size detail is concrete: hyperphosphatemia is common among roughly 500,000 dialysis patients in the U.S. and 4 million worldwide. The company highlights the practical downside of existing phosphate binders: high pill burden and GI tolerability problems that drive poor adherence. AP306 is expected to enter a Phase 2b study later this year; Alebund published Phase 2a data in January 2025 showing a significant reduction in serum phosphate with favorable safety/tolerability. What to watch: whether “active transport” inhibition translates into clinically meaningful control with a simpler regimen than binder-heavy standards.

The TIL resurgence is colliding with modern gene editing. A BioSpace/ACCESS Newswire release says Grit Biotechnologies received FDA IND clearance for GT307, described as a next-generation gene-edited tumor-infiltrating lymphocytes (TIL) therapy. The mechanistic hook is specific: GT307 uses high-fidelity CRISPR/AaCas12bMAX editing to knock out key immune regulatory genes, with the stated goal of addressing TIL exhaustion in the tumor microenvironment and insufficient persistence in vivo. Manufacturing is part of the story: uBriGene says it used a fully closed and automated production system (“TIL‑Turbo”) to reduce variability and contamination risk, and notes robust expansion within ~three weeks. The release claims the platform has completed 10+ GMP TIL manufacturing runs, which is the kind of operational detail that matters when you move from “cool biology” to “treatable product.” Next step is simple and hard: first-in-human studies will decide whether the edit set actually buys durability without breaking safety.

Cleveland’s shape is starting to look like “playoff problem” again, because the defense travels. AP reports Evan Mobley scored 25 points and the Cavaliers beat Milwaukee 112–100. The game turned on control more than fireworks: Cleveland dictated pace and kept Milwaukee from getting comfortable stretches of transition offense. The injury note is the practical “next step”: the Bucks’ James Harden left the game due to lower back tightness, and any missed time in March reshapes seeding math fast. From a roster-reading angle, Mobley being this assertive matters because it gives Cleveland a second interior scoring pillar when the perimeter gets trapped. If you’re tracking contenders, this is the kind of “non-highlight” win that often shows the team’s floor.

Minnesota’s offense can look blunt until it suddenly isn’t. An AP recap syndicated via the Bozeman Daily Chronicle says Julius Randle scored 32 points to lead the Timberwolves past the Suns 116–104. The Suns’ slide is the headline context — this was their third straight loss — and in the West, those streaks don’t stay “small” for long. The game also reads like a reminder that the Wolves don’t need perfect shot quality if they can generate second chances and keep opponents out of rhythm. For Phoenix, the next step is less tactical than structural: they need stable lineup minutes and defensive buy-in, or the remaining schedule becomes a sprint just to stay out of the play-in mess.

This paper is useful because it answers the real question clinicians ask: not “are infections a risk?” but “how does the risk accumulate over time?” A systematic review and meta-analysis (25 studies, 3,202 patients) compared infection outcomes for commercially approved CD19 CAR T therapies versus CD3×CD20 bispecific antibodies in B-cell NHL. The headline is subtle: per patient, all-grade infection rates were similar (0.44 vs 0.54), and grade ≥3 infection rates were also similar (0.16 vs 0.22). But when normalized by exposure time, bispecifics had higher infection rates per patient-month (0.0397 vs 0.0167) and higher grade ≥3 infections per patient-month (0.0165 vs 0.0069). Infection-related mortality looked similar across both modalities (0.04 vs 0.03 per patient). The practical implication is sequencing logic: if bispecifics are used as indefinite therapy, supportive care and infection prophylaxis aren’t “add-ons” — they’re part of the efficacy package.

The myeloma field has reached a new kind of difficulty: too many effective T-cell redirecting options, not enough clarity on the best order. This review focuses on CAR T cells and bispecific antibodies in relapsed/refractory multiple myeloma, highlighting that most current regimens don’t show a clear survival “plateau.” That reality forces a sequencing world where patients may receive multiple T-cell redirecting agents over time. The paper emphasizes that modalities differ in toxicity and administration features, so “best therapy” becomes “best therapy for this patient, now.” It explicitly calls out tumor- and patient-specific features as decision drivers, plus the need for tailored trials and real-world analyses to make evidence-based recommendations. The next step is algorithmic: once resistance mechanisms and immunologic states are better mapped, sequencing will likely become more mechanistically guided rather than preference-driven.

Venice is turning “day-trip friction” into policy infrastructure. The official Venezia Unica portal states that application dates for the Contributo di Accesso in 2026 have been officially established, with the main period running 3 April to 26 July 2026. The fee is framed as a daily payment, and the portal highlights a €5 price when paid by the “quart’ultimo” day before the visit date (i.e., a built-in incentive to decide early). In practice, that means trip planning becomes less spontaneous — which is exactly the point if the city wants fewer peak-day surges. The portal also foregrounds exemptions and category rules, hinting that enforcement and verification are going to be part of the visitor experience. Next step: watch whether the fee becomes a pricing lever (peak-day vs off-peak) or stays a flat behavioral nudge.

Wer Puglia abseits von Hochsommer-Strand sieht, sieht oft das stärkere Produkt: Business, Kultur, Events. Puglia.com beschreibt BTM Italia 2026 (Bari, Fiera del Levante) als großen Branchen-Treff, unterstützt von Region Puglia und Pugliapromozione, mit Laufzeit bis 27. Februar. Die harten Zahlen sind beeindruckend: 545 Aussteller und 100 internationale Buyer, die teils bereits vorab zu Fam-Trips in der Region waren. Das Motto „ri-genera“ wird als Anspruch formuliert, Tourismus nicht als statisches Produkt zu verkaufen, sondern als Prozess, der Territorien respektiert und neue Generationen anspricht. Praktisch heißt das: mehr Segmente (Gusto/Enogastro, Wedding, neue Spezialbereiche) und mehr internationale Distribution. Next step für Reisende: Wenn aus solchen Messen neue Flug-/Zug-Koop, Micro-Season-Events oder „Workation“-Pakete entstehen, merkt man das oft zuerst an besseren Schultersaison-Angeboten.

Puglia’s best travel trick is giving you a reason to come when it’s not packed. Puglia.com reports that the Sudestival 2026 — a winter-long auteur cinema festival in Monopoli — closed with a final night on Saturday, 14 March. The guest of honor was Riccardo Scamarcio, set to receive the Premio Eccellenze del Cinema, and the article explicitly ties the festival’s identity to cultural prestige rather than “events for Instagram.” A small but telling detail: the festival highlights an Eco Event Plastic Free label, which signals that sustainability is now part of brand positioning even for cultural programming. For travelers, this is the kind of anchor that makes shoulder-season trips feel intentional: one fixed cultural night, then slow-food lunches and coastal walks without July density. Next step: if you’re planning Puglia in 2026, track these cultural calendars the same way you track beach weather — they’re often the difference between “nice” and “memorable.”

Wien bleibt in einer Disziplin konstant: neue Orte erfinden, die man schnell als „eh schon immer da“ abspeichert. Goodnight.at sammelt für März 2026 eine ganze Reihe neuer Restaurants, Cafés und Bars — und man kann daraus erstaunlich klare Mikro-Trends lesen. Malma Art Café (1050) kombiniert Kaffee mit „macht’s euch kreativ“ (Malen/Basteln/Workshops), also Community statt nur Konsum. Papa Duck (1060) setzt auf Inari-Tofu-Taschen als Signature, plus Dip-Nudeln in Varianten (Tempura Shrimps, Curry, Ente) — ein sehr „konzentriertes“ Konzept. Die Krawall Bar & Deli (1070) ist oben Tagesbar/Deli, unten Cocktailbar mit DJ-Pult und Tanzfläche; das ist fast schon ein Bauplan für Abende, die länger werden als geplant. Und mit dem Davy Art Space (Lindengasse 51) landet die Idee „Kunst + Kulinarik + Community“ im Fixbetrieb. Nächster Schritt: Wenn du nur zwei Spots probieren willst, nimm einen Tages- und einen Nacht-Ort — so bekommst du die Bandbreite ohne Wochenend-Stress.

If you want the quickest “what’s actually happening tomorrow?” pulse in Vienna’s art ecosystem, eSeL remains ridiculously efficient. The “Tomorrow” page aggregates openings, exhibitions, and event listings for Thursday, 19 March 2026 into a single, scrollable overview. It’s not a single story — it’s a routing layer: you can decide whether you want gallery energy, museum seriousness, or something more performance-adjacent. The real value is that it compresses decision time: you don’t need ten tabs to build a plan. For groups, it also helps you pick an anchor event and then cluster nearby stops. Next step: treat it like a menu — pick one “must”, one “nice”, and leave the rest for next week, otherwise you’ll overbook yourself before you even leave home.

WIENXTRA’s Wochentipps are basically parenting operations: one page, low drama, lots of options. The press page collects weekly kid and family recommendations, which makes it a reliable starting point when you need something concrete after school or on the weekend. The value isn’t one “perfect” event — it’s the breadth, because kids’ energy, weather, and schedules are never stable. It also tends to include a mix of free/low-cost options and bigger ticketed events, so you can plan to your week, not to an ideal version of your week. Use it as a filter: pick one outdoor option, one indoor backup, and you’re done. Next step: if you’re already looking at Vienna cultural listings elsewhere, use WIENXTRA as the “sanity check” for what’s actually family-proof.

Shortlist: family day trips, outdoors-first plans, “good enough” ideas that work even when the weather flips. 1000things rounds up excursion suggestions for the Easter break across Austria — the kind of list you don’t follow end-to-end, but mine for the one option that fits your kids’ age and your tolerance for logistics. The practical value is variety: some ideas are close-to-city, others are “make a day of it,” which helps you match energy and time. Lists like this also reduce decision fatigue, because you’re picking from a curated set instead of infinite search results. Next step: pick one low-effort trip and schedule it early in the break — it buys you momentum (and fewer “what are we doing today?” loops).